Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK begins shipping FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT
GSK completes acquisition of Sierra Oncology
A California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
Inaugural grant awarded to the HealthTree Foundation, a non-profit organization who will address disparities in care in multiple myeloma
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
GSK and Sanofi announce positive data from their vaccine trial
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate
GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA
Learn about the abstracts we are presenting focusing on approved therapies, as well as investigational medicines.
Local budding biologists explore the past, present and future during GSK Science in the Summer™ in partnership with the Franklin Institute
Free summer STEM enrichment program allows students to take on the role of biologists
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Learn about our first quarter 2022 results
US Food and Drug Administration accepts New Drug Application for daprodustat
Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
GSK and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
This research was published in the Infectious Diseases Society of America’s Open Forum Infectious Diseases.
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
This approval marks the first time a long-acting HIV treatment is available for the adolescent population.
US Food and Drug Administration revises Emergency Use Authorization for Sotrovimab due to Omicron BA.2 subvariant
The US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
GSK to demonstrate its commitment to improving outcomes for patients with gynecologic cancer at the 2022 SGO Annual Meeting
The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022.